March 28th, 2021
•The glioma stem cells (GSCs) are a small fraction of cancer cells which play essential roles in tumor initiation, angiogenesis, and drug resistance in glioblastoma (GBM), the most prevalent and devastating primary brain tumor. The presence of GSCs makes the GBM very refractory to most of individual targeted agents, so high-throughput screening methods are required to identify potential effective combination therapeutics. The protocol describes a simple workflow to enable rapid screening for potential combination therapy
Tags
Related Videos
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG)
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
A Melanoma Patient-Derived Xenograft Model
Physiologic Patient Derived 3D Spheroids for Anti-neoplastic Drug Screening to Target Cancer Stem Cells
Using Human Induced Pluripotent Stem Cells for the Generation of Tumor Antigen-specific T Cells
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Combined Conditional Knockdown and Adapted Sphere Formation Assay to Study a Stemness-Associated Gene of Patient-derived Gastric Cancer Stem Cells
Drug Screening of Primary Patient Derived Tumor Xenografts in Zebrafish
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Copyright © 2024 MyJoVE Corporation. 판권 소유